Inactivation of Smad4 is a prognostic factor in intrahepatic cholangiocarcinoma

Chinese Medical Journal

Volumn 126, Issue 16, 2013, Pages 3039-3043

  Yan, Xue Qiang ^a   Zhang, Wei ^b   Zhang, Bi Xiang ^b   Liang, Hui Fang ^b   Zhang, Wan Guang ^b   Chen, Xiao Ping ^b  

^a Wuhan Medical and Health Center for Women and Children   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Clinical pathology; Immunohistochemistry; Intrahepatic cholangiocarcinoma; Metastasis; Smad4

Indexed keywords

MESSENGER RNA; PEROXIDASE; SMAD4 PROTEIN;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMAD4 GENE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84882279362     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20121235     Document Type: Article

References (23)

1. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357.
2. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006; 94: 1751-1758.
3. Fu XH, Tang ZH, Zong M, Yang GS, Yao XP, Wu MC. Clinicopathologic features, diagnosis and surgical treatment of intrahepatic cholangiocarcinoma in 104 patients. Hepatobiliary Pancreat Dis Int 2004; 3: 279-283.
4. Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg 2002; 183: 679-685.
5. Suzuki S, Sakaguchi T, Yokoi Y, Okamoto K, Kurachi K, Tsuchiya Y, et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg 2002; 26: 687-693.
6. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (New York, NY) 1996; 271: 350-353.
7. Barrett MT, Schutte M, Kern SE, Reid BJ. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res 1996; 56: 4351-4353.
8. Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi T, Saji S, et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 1996; 56: 2718-2720.
9. McCarthy DM, Hruban RH, Argani P, Howe JR, Conlon KC, Brennan MF, et al. Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases. Mod Pathol 2003; 16: 272-278.
10. Schwarte-Waldhoff I, Klein S, Blass-Kampmann S, Hintelmann A, Eilert C, Dreschers S, et al. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene 1999; 18: 3152-3158.
11. Baldus SE, Schwarz E, Lohrey C, Zapatka M, Landsberg S, Hahn SA, et al. Smad4 defciency in cervical carcinoma cells. Oncogene 2005; 24: 810-819.
12. Lee KT, Chang WT, Wang SN, Chuang SC, Chai C Y, Hu SW. Expression of DPC4/Smad4 gene in stone-containing intrahepatic bile duct. J Surg Oncol. 2006; 94: 338-343.
13. Shiraishi K, Kusano N, Okita S, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in biliary tract cancers. Oncology 1999; 57: 42-49.
14. Hahn SA, Bartsch D, Schroers A, Galehdari H, Becker M, Ramaswamy A, et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998; 58: 1124-1126.
15. Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 2001; 91: 1332-1341.
16. Kang YK, Kim WH, Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 2002; 33: 877-883.
17. Chuang SC, Lee KT, Tsai KB, Sheen PC, Nagai E, Mizumoto K, et al. Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg 2004; 28: 995-1000.
18. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
19. Volmer MW, Radacz Y, Hahn SA, Klein-Scory S, Stuhler K, Zapatka M, et al. Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a "secretom" analysis. Proteomics 2004; 4: 1324-1334.
20. Gassmann P, Enns A, Haier J. Role of tumor cell adhesion and migration in organ-specific metastasis formation. Onkologie 2004; 27: 577-582.
21. Donadio AC, Durand S, Remedi MM, Frede S, Ceschin DG, Genti-Raimondi S, et al. Evaluation of stromal metalloproteinases and vascular endothelial growth factors in a spontaneous metastasis model. Exp Mol Pathol 2005; 79: 259-264.
22. Maitra A, Molberg K, Albores-Saavedra J, Lindberg G. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol 2000; 157: 1105-1111.
23. Losi L, Bouzourene H, Benhattar J. Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep 2007; 17: 1095-1099.